Anterior Ischemic Optic Neuropathy Associated with Udenafil

In-Gun Kim¹, Dae Yune Kim¹,²

¹Department of Ophthalmology, Maryknoll Hospital, Busan, Korea
²Lee Eye Clinic, Busan, Korea

Udenafil (Zydena, Dong-A Phamaceutical, Seoul, Korea) is a drug used in urology to treat erectile dysfunction and belongs to a class of drugs called phosphodiesterase type 5 (PDE 5) inhibitors. Other erectile dysfunction drugs such as sildenafil, tadalafil and vardenafil are also PDE5 inhibitors. The authors report the first literature case of anterior ischemic optic neuropathy (AION) associated with udenafil.

Case Report

A 54-year-old male complained of decreased visual field in his right eye. He also had a history of sexual dysfunction, for which he was prescribed udenafil. He took his first dose of 100 mg udenafil three days before his visit to our clinic. The next day he found that his eye was mildly irritated, and he had a mild headache. He discussed these symptoms with his urologist, and his symptoms subsided on their own after several hours. One day before his visit to our clinic, he took his second dose of udenafil. The following morning, approximately 12 hours later, he reported blurred vision and a decrease in the visual field of his right eye. This patient did have a 20-year history of smoking but no history of either hypertension or hypotension, diabetes mellitus, hyperlipidemia, or cardiovascular disease. Upon examination, his best-corrected visual acuity (BCVA) was 20 / 25 in the right eye and 20 / 20 in the left eye. A pupillary examination revealed a right-sided relative afferent pupillary defect. Ocular motility was normal, and the biomicroscopy of the anterior segment was unremarkable. A dilated fundus examination of the right eye revealed prominent swelling of the disc with a disc rim hemorrhage (Fig. 1). Fundoscopy of the left eye revealed a healthy but crowded disc with a cup-to-disc ratio of 0.2 (Fig. 1). Fundus fluorescein angiography showed both an inferior choroidal filling delay and an inferior sector filling delay of the optic disc in the arteriovenous phase as well as diffuse leakage of the optic disc in the late phase. Optical coherent tomography revealed increased thickness of the retinal nerve fiber layer, especially in the area of the inferior disc. The patient was counseled to discontinue the use of udenafil and to monitor his blood pressure regularly. The disc swelling was resolved with residual optic atrophy one month after discontinuing the use of udenafil.

Key Words: Anterior ischemic optic neuropathy, Erectile dysfunction, Udenafil
Fig. 1. (A) Fundus photograph of the right eye shows prominent swelling of the disc with a disc rim hemorrhage. (B) Fundus photograph of the left eye shows a healthy appearing but crowded disc with a cup-to-disc ratio of 0.2.

Fig. 2. Fluorescein angiography shows an inferior choroidal filling delay and inferior sector filling delay of the optic disc in the arteriovenous phase (A) as well as diffuse leakage of the optic disc in the late phase (B).

Fig. 3. Humphrey 30-2 visual field of the left (A) and right eyes (B) at the initial examination.
studies have demonstrated that delayed optic disc filling occurs without impairment of the choroidal circulation, which suggests that the vasculopathy is located in the paroptic branches of the SPCA after their branching from the choroidal branches rather than in the short ciliary arteries. This results in an erection. PDE5 is a naturally occurring enzyme that is found in high concentrations in the corporis cavernosum. It is hypothesized that the mild hypotensive effect of PDE5 inhibitors accentuate physiological nocturnal hypotension, which may result in ischemia of the optic nerve head and compartment syndrome in a susceptible disc. An alternative explanation is that these medications reduce optic nerve head perfusion or disrupt the ability to autoregulate due to the potentiation of nitric oxide. There have been several case reports that have described AION in users of PDE5 inhibitors. Egan and Pomeranz [11] have reported on sildenafil-associated AION, and Cunningham and Smith [12] have also reported a case of anterior ischemic optic neuropathy associated with sildenafil (Viagra; Pfizer, New York, NY, USA). Bollinger and Lee [13] have reported a recurrent visual field defect and ischemic optic neuropathy associated with tadalafil rechallenge. There have been no published case reports that have linked an episode of AION to udenafil.

The commonly associated systemic diseases include arterial hypertension, diabetes mellitus, hyperlipidemia, cerebrovascular accidents, and arteriosclerosis [14]. Various associated systemic diseases may interfere with the autoregulation of blood flow in the optic nerve head and make the optic nerve head vulnerable to AION. Lee et al. [15] have reported that hypertension, high cholesterol and decreased cup-to-disc ratio were observed in more than 60% of Korean patients with AION and thereby defined these as major risk factors. Chung et al. [16] have reported that, of the 137 patients identified with AION in their study, the 28 smokers were statistically younger, with a mean age of 51 years, than the 83 nonsmokers, who had a mean age of 64 years. They concluded that cigarette smoking is an important risk factor in the development of AION, and that the cessation of
smoking appears to reduce the risk of AION to that of the nonsmoking population. Lee et al. [15] have also reported that, of the 48 patients with AION in their study, the mean age of the nine smokers, was less than the 50.5 years of the nonsmokers. Of the nine smokers, four had smoking history as the only risk factor for AION. The authors also suggested that smoking is an important risk factor of AION and may be the only risk factor in younger patients.

The differential diagnosis of AION included functional visual loss, retinopathy (hypertensive retinopathy, central serous retinopathy, congenital maculopathy, pigmentary retinopathy, amelanotic melanoma, and cellophane maculopathy), amblyopia, glaucoma, keratoconus, pseudopapilledema, miscorrected refractive error, Leber’s congenital amaurosis, and cortical visual loss [16].

Although the fundoscopic image and fundus fluorescein angiography were most consistent with AION, the possibility of inflammatory optic neuropathy (optic neuritis) was also considered. Laboratory testing revealed no evidence of systemic inflammation. The neurologic examination was also normal, and the MRI scan of the brain with gadolinium enhancement demonstrated that the optic nerves appeared normal, and the lack of white matter lesions were not suggestive of demyelinating disease.

The actual duration of the pharmacologic effect of udenafil is approximately 24 hours. Patients are told to take udenafil approximately 90 to 120 minutes prior to sexual intercourse. Since the patient in this case study took the udenafil at night and then fell asleep after sexual intercourse, he noticed the visual field defect the following morning. We believe that udenafil may have contributed to the episode of AION in this patient. The risk factors of this patient were a decreased cup-to-disc ratio and a smoking history. The udenafil may have sufficiently accentuated his physiologic nocturnal hypotension to decrease the perfusion pressure in the posterior ciliary arteries. This may have resulted in ischemia of the disc that was already predisposed to AION due to the anatomic disc-at-risk configuration. The temporal relationship between the dose of udenafil and the onset of visual field defect make it difficult to accept the notion that these were unrelated coincidental events.

During the evaluation of patients with signs and symptoms of AION, a complete review of medications, including questions about udenafil use, is essential. Patients may be reluctant to inform their doctors about their use of udenafil as a result of the stigma that is associated with erectile dysfunction.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

References

1. Hattenhauer MG, Leavitt JA, Hodge DO, et al. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1997;123:103-7.
2. Knox DL, Kerrison JB, Green WR. Histopathologic studies of ischemic optic neuropathy. Trans Am Ophthalmol Soc 2000;98:203-20.
3. Flaharty PM, Sergott RC, Lieb W, et al. Optic nerve sheath decompression may improve blood flow in anterior ischemic optic neuropathy. Ophthalmology 1993;100:297-302.
4. Arnold AC, Hepler RS. Fluorescein angiography in acute nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1994;117:222-30.
5. Oto S, Yilmaz G, Cakmakci S, Aydin P. Indocyanine green and fluorescein angiography in nonarteritic anterior ischemic optic neuropathy. Retina 2002;22:187-91.
6. Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol 1994;117:603-24.
7. Beck RW, Savino PJ, Repka MX, et al. Optic disc structure in anterior ischemic optic neuropathy. Ophthalmology 1984;91:1334-7.
8. Burde RM. Optic disk risk factors for nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1993;116:759-64.
9. Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999;83:35C-44C.
10. Danesh-Meyer HV, Levin LA. Erectile dysfunction drugs and risk of anterior ischaemic optic neuropathy: casual or causal association? Br J Ophthalmol 2007;91:1551-5.
11. Egan R, Pomeranz H. Sildenafil (Viagra) associated anterior ischemic optic neuropathy. Arch Ophthalmol 2000;118:291-2.
12. Cunningham AV, Smith KH. Anterior ischemic optic neuropathy associated with viagra. J Neuroophthalmol 2001;21:22-5.
13. Bollinger K, Lee MS. Recurrent visual field defect and ischemic optic neuropathy associated with tadalfil rechallenge. Arch Ophthalmol 2005;123:400-1.
14. Hayreh SS, Joos KM, Podhajsky PA, Long CR. Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1994;118:766-80.
15. Lee YJ, Kim MK, Hwang JM. Differential diagnosis of optic neuropathy. J Korean Ophthalmol Soc 2001;42:614-7.
16. Chung SM, Gai CA, McCrarya JA 3rd. Nonarteritic ischemic optic neuropathy: the impact of tobacco use. Ophthalmology 1994;101:779-82.